Project ProCorde

The members of the team look back on several decades of experience in cardiovascular research. In 2000, the foundation of Procorde laid a common basis to advance research projects, and to develop nature-based antibodies, fusion proteins and peptides. From 2007 on, a significant financing of the successor company Corimmun enabled further clinical development of the most promising peptides and antibodies, which had been identified by using these technologies.

The Team

History

The team has initiated most of the current projects in the first years after founding Procorde (2000). During this period, cooperations with large enterprises (e.g. Sanofi-Aventis) have been carried out successfully. Starting 2007, relevant funding of the successor company Corimmun allowed further clinical development of the most promising drugs. In June 2012, Corimmun GmbH was sold to Janssen-CILAG GmbH, Neuss, a subsidiary of Johnson + Johnson, New Brunswick, NJ, USA.